Investor Presentation March 2023
Inotiv's Core Focus
Full-Spectrum Drug Discovery & Development
Provider
DSA
Drug Discovery & Translational Sciences
Clinical Development
Preclinical Development
|
||
III
Target Validation
Lead Series
Optimization
Pharmacology (Multiple Therapeutic Areas)
General Toxicology (GLP)
Genetically Engineered Models
Drug Metabolism & Pharmacokinetics
Cellular and Molecular Biology
Proteomics and Biomarker Discovery
Comprehensive Discovery Toxicology
Safety Pharmacology
Genetic Toxicology
Med Device Surgical Models/Toxicology
Histopathology (+ Clinical Pathology)
Discovery Formulation Support
Large & Small Animal Research Models
RMS Teklad Diets & Bedding
Histology & Pathology (GLP)
Developmental & Reproductive Toxicology (GLP)
Safety Pharmacology Battery Support (GLP)
Genetic Toxicology (GLP)
Computational and in vitro toxicology
Regulated Bioanalysis (GLP)
Medical Device Toxicology (GLP)
Program Management
Biotherapeutics Analysis & Support (GLP)
Biomarker Development & Validation (GLP)
Large & Small Animal Research Support
Teklad Diets & Bedding
Research Model Support Services
Clinical Bioanalysis (GCLP)
Biomarker Utilization + Clinical Trial Support
(GCLP)
Biotherapeutics Support (GCLP)
Bioequivalence (GXP)
Core Scientific Capability & Service (SCS)
Internal Investment in Core SCS (1)
(1) Represents internally developed, pre-revenue
Initiatives currently being commercialized
7View entire presentation